Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.verified

LCTX

Price:

$1.27

Market Cap:

$316.61M

Lineage Cell Therapeutics, Inc. (LCTX) operates as a biotechnology firm in the clinical trial phase, dedicated to pioneering innovative cell-based treatments for various degenerative conditions across the United States and globally. The company's pipeline features several key therapeutic candidates: OpRegen, a replacement therapy utilizing retinal pigment epithelium cells, is currently undergoing Phase I/IIa clinical trials to address dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, is being evaluated in Phase I/IIa multicenter clinical studies for individuals suffering from acute spinal cord injuries. VAC2, an allogeneic cancer immunotherapy employing ...[Read more]

Industry

Biotechnology

IPO Date

1992-03-05

Stock Exchange

AMEX

Ticker

LCTX

The Enterprise Value as of June 2026 (TTM) for Lineage Cell Therapeutics, Inc. (LCTX) is 283.06M

According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 283.06M. This represents a change of -6.85% compared to the average of 303.88M of the last 4 quarters.

Lineage Cell Therapeutics, Inc. (LCTX) Historical Enterprise Value (quarterly & annually)

How has LCTX Enterprise Value performed in the past?

The mean historical Enterprise Value of Lineage Cell Therapeutics, Inc. over the last ten years is 209.89M. The current 283.06M Enterprise Value has changed 13.39% with respect to the historical average. Over the past ten years (40 quarters), LCTX's Enterprise Value was at its highest in in the June 2021 quarter at 395.76M. The Enterprise Value was at its lowest in in the March 2025 quarter at 56.44M.

Quarterly (TTM)
Annual

Average

209.89M

Median

201.01M

Minimum

57.32M

Maximum

350.09M

Lineage Cell Therapeutics, Inc. (LCTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 503.47%

Maximum Annual Enterprise Value = 350.09M

Minimum Annual Increase = -63.19%

Minimum Annual Enterprise Value = 57.32M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025345.92M503.47%
202457.32M-63.19%
2023155.71M-18.56%
2022191.20M-45.39%
2021350.09M48.77%
2020235.32M87.96%
2019125.20M32.96%
201894.16M-55.34%
2017210.82M-36.73%
2016333.20M15.02%

Lineage Cell Therapeutics, Inc. (LCTX) Average Enterprise Value

How has LCTX Enterprise Value performed in the past?

The current Enterprise Value of Lineage Cell Therapeutics, Inc. (LCTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

186.32M

5-year avg

220.05M

10-year avg

209.89M

Lineage Cell Therapeutics, Inc. (LCTX) Enterprise Value vs. Peers

How is LCTX’s Enterprise Value compared to its peers?

Lineage Cell Therapeutics, Inc.’s Enterprise Value is less than Neurogene Inc. (344.80M), less than Ocugen, Inc. (411.05M), greater than Benitec Biopharma Inc. (109.56M), less than ADC Therapeutics S.A. (323.90M), less than Autolus Therapeutics plc (364.21M), greater than Fulcrum Therapeutics, Inc. (142.29M), greater than PureTech Health plc (189.76M), less than Galectin Therapeutics Inc. (297.44M), less than Omeros Corporation (940.92M), less than RAPT Therapeutics, Inc. (923.92M),

Build a custom stock screener for Lineage Cell Therapeutics, Inc. (LCTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lineage Cell Therapeutics, Inc. (LCTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Lineage Cell Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the 3-year average Enterprise Value for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the 5-year average Enterprise Value for Lineage Cell Therapeutics, Inc. (LCTX)?

How does the current Enterprise Value for Lineage Cell Therapeutics, Inc. (LCTX) compare to its historical average?